User login
Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
Nivolumab: first immunotherapy approved for lung cancer
The approval of nivolumab in early 2015 by the US Food and Drug Administration (FDA) for the treatment of squamous cell non-small-cell lung cancer (NSCLC) marks a second approval for this drug, following a 2014 approval for metastatic melanoma. Approved 3 months ahead of schedule, nivolumab is the first immunotherapy to be approved for the treatment of lung cancer. The drug can help to reinstate the antitumor immune response by targeting the programmed cell death-1 (PD-1) receptor, an “immune checkpoint” protein found on the surface of activated T cells that is involved in inhibiting T-cell activity.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(9)
Topics
Page Number
312-315
Legacy Keywords
nivolumab, non-small-cell-lung cancer, NSCLC, immunotherapy, PD-1, PD-L1, CTLA-4, checkpoint inhibitor, CheckMate
Sections
Article PDF
Article PDF
The approval of nivolumab in early 2015 by the US Food and Drug Administration (FDA) for the treatment of squamous cell non-small-cell lung cancer (NSCLC) marks a second approval for this drug, following a 2014 approval for metastatic melanoma. Approved 3 months ahead of schedule, nivolumab is the first immunotherapy to be approved for the treatment of lung cancer. The drug can help to reinstate the antitumor immune response by targeting the programmed cell death-1 (PD-1) receptor, an “immune checkpoint” protein found on the surface of activated T cells that is involved in inhibiting T-cell activity.
Click on the PDF icon at the top of this introduction to read the full article.
The approval of nivolumab in early 2015 by the US Food and Drug Administration (FDA) for the treatment of squamous cell non-small-cell lung cancer (NSCLC) marks a second approval for this drug, following a 2014 approval for metastatic melanoma. Approved 3 months ahead of schedule, nivolumab is the first immunotherapy to be approved for the treatment of lung cancer. The drug can help to reinstate the antitumor immune response by targeting the programmed cell death-1 (PD-1) receptor, an “immune checkpoint” protein found on the surface of activated T cells that is involved in inhibiting T-cell activity.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(9)
Issue
The Journal of Community and Supportive Oncology - 13(9)
Page Number
312-315
Page Number
312-315
Topics
Article Type
Display Headline
Nivolumab: first immunotherapy approved for lung cancer
Display Headline
Nivolumab: first immunotherapy approved for lung cancer
Legacy Keywords
nivolumab, non-small-cell-lung cancer, NSCLC, immunotherapy, PD-1, PD-L1, CTLA-4, checkpoint inhibitor, CheckMate
Legacy Keywords
nivolumab, non-small-cell-lung cancer, NSCLC, immunotherapy, PD-1, PD-L1, CTLA-4, checkpoint inhibitor, CheckMate
Sections
Citation Override
JCSO 2015;13:312-315
Disallow All Ads
Alternative CME
Article PDF Media
Document